echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > WuXi Junuo CAR-T product clinical application for new indications was approved

    WuXi Junuo CAR-T product clinical application for new indications was approved

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 20, WuXi Junuo announced that the clinical trial application of Ruikiolanza injection for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) has been approved.


    Ruiki Orenza Injection (trade name: Benoda) is a CD19-targeting drug independently developed by WuXi Ju Nuo on the basis of the CAR-T cell technology platform of Ju Nuo Medical, a subsidiary of Bristol-Myers Squibb (BMS).


    At present, WuXi Junuo is still exploring the efficacy of Ruiki Aurenzai Injection in the treatment of more indications


    It is reported that the approval of Ruikiolenza injection is a phase 1 open-label, single-arm, dose-escalating study (JWCAR029-006 study) in China, which aims to evaluate the drug in the treatment of r/r B- Safety, tolerability, pharmacokinetics, and determination of phase 2 recommended dose (RP2D) in children and young adult subjects with ALL


    Published data show that B-ALL is the most common malignant tumor in children, and resistance to chemotherapy drugs usually leads to relapse or disease progression in patients, and patients after relapse often have a very poor survival rate


    References:

    [1] WuXi Junuo Announces Approval of Clinical Trial Application of Benoda® for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Children and Young Adults.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.